Frontage Laboratories’ new toxicology facility in Suzhou, China was granted an “Experimental Animal Use License” by Jiangsu’s Provincial Department of Science and Technology, following an on-site inspection and review of recently completed construction.
 
The custom-designed 200,000 sq.-ft, 100 animal room facility will house all major laboratory species (including Non-Human Primates) and will undertake GLP and non-GLP in vivo and in vitro toxicology, safety and drug metabolism studies to support drug and chemical registration in China and globally.  The design includes supporting labs for bioanalysis, chemistry, clinical pathology, histology, genetic toxicology and safety pharmacology, and segregated housing areas for each species.
 
Frontage plans to launch a program of single and repeat dose validation studies in all major species by 2Q22 as part of the process to obtain certification for the conduct of commercial GLP studies, which the company anticipates receiving by late 2022.  In addition, Frontage expects to begin offering non-GLP toxicology and drug metabolism studies at the Suzhou site in the near future.
 
Frontage’s Executive Vice President of Global Safety & Toxicology , Glenn Washer said, “With the addition of the Suzhou, China site as our third toxicology facility – along with our recently acquired Experimur LLC toxicology business in Chicago, IL and our existing toxicology site in Concord, OH – Frontage’s ability to support our clients’ safety & toxicology programs will be greatly expanded.  These three facilities will address all categories of drug development toxicology from early discovery toxicology, to IND-enabling and through later NDA-enabling toxicology, including developmental and reproductive toxicology and routine and transgenic carcinogenicity bioassays.”